Four analysts polled by Capital IQ expected a GAAP loss of $0.48 per share.
Sales rose 20% year over year to $130.7 million, according to an earnings statement early Wednesday for the quarter ended Oct. 30. Four analysts surveyed by Capital IQ expected revenue of $127.3 million.
In fiscal Q4, the company anticipates net sales of between $175 million and $180 million, compared with a market projection compiled by Capital IQ of $167 million.
For the full-year fiscal 2022, it sees revenue in the range of $675 million to $725 million. In its Q2 results Aug. 24, the company had guided to full-year net sales of $502 million, which was a $12 million increase over management's guidance set out in Q1. Four analysts surveyed by Capital IQ expected fiscal 2022 revenue to be $520.9 million.
It also anticipates reporting positive quarterly EPS beginning in the back half of 2022.
|Insider Buy: Coinbase Global|
|-- Earnings Flash (API) AGORA Reports Q2 Revenue $41M|
|-- Earnings Flash (DN) DELTA 9 CANNABIS Reports Q2 L...|
|Insider Sell: Oak Street Health|
|Insider Sell: Guardant Health|